

Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
Date of first issue: 02.01.2018

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifier

LYNPARZA CAPSULES

Details of the supplier of the safety data sheet

: ASTRAZENECA PTY LTD Emergency Telephone
PO Box 131 +44 (0) 1235 239 670
66 Talavera Rd, North Ryde
NSW 2113
AUSTRALIA
+61 2 9978 3500

SafetyDataSheets.AlderleyPark@astrazeneca.com

Alternative Names

AZD2281 Capsules
CO-CE 42
KU-0059436 Capsules
Olaparib capsules
CAS No. : Not applicable

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Potential anti-cancer agent

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1B
Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Bone marrow, lymph node, spleen, Liver, Gastro-intestinal system)
Chronic aquatic toxicity : Category 3

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360 May damage fertility or the unborn child.
H372 Causes damage to organs (Bone marrow, lymph node, spleen, Liver, Gastro-intestinal system) through prolonged or repeated exposure if swallowed.
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.

Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
 Date of first issue: 02.01.2018

P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
 P264 Wash skin thoroughly after handling.
 P273 Avoid release to the environment.
 P281 Use personal protective equipment as required.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Hazardous components which must be listed on the label:

Olaparib

Other hazards which do not result in classification

Evidence of genotoxicity and should be treated with caution.
 May cause reduced resistance to infection and increased risk of bleeding.
 May form explosible dust-air mixture if dispersed.
 See Section 11.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous components

Chemical name	CAS-No.	Concentration (% w/w)
Olaparib	763113-22-0	10

SECTION 4. FIRST AID MEASURES

If inhaled : Remove patient from exposure, keep warm and at rest. Obtain medical attention.

In case of skin contact : Remove contaminated clothing. After contact with skin, wash immediately with plenty of water. If symptoms (irritation or blistering) occur obtain medical attention.

In case of eye contact : Irrigate with eyewash solution or clean water, holding the eyelids apart, for at least 10 minutes. Obtain medical attention.

If swallowed : Provided the patient is conscious, wash out mouth with water and give 200-300 ml of water to drink. Do NOT induce vomiting as a First-Aid measure. Obtain immediate medical attention.

Most important symptoms and effects, both acute and delayed : Refer to sections 2 and 11
 May damage fertility or the unborn child.
 Causes damage to organs through prolonged or repeated exposure if swallowed.

SAFETY DATA SHEET



Version	Revision Date:	SDS Number:	Date of last issue: -
2.0	02.01.2018	10313	Date of first issue: 02.01.2018

Notes to physician : Symptomatic treatment and supportive therapy as indicated. Emergency medical treatment advice varies within different countries. For further information consult the Local National Poisons Information Services.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : water spray, foam, dry powder or CO₂.

Unsuitable extinguishing media : Avoid high pressure media which could cause the formation of a potentially explosible dust-air mixture.

Specific hazards during firefighting : If involved in a fire, it may burn and emit noxious and toxic fumes.

Special protective equipment for firefighters : A self contained breathing apparatus and full protective clothing must be worn in fire conditions. Prevent fire extinguishing water from contaminating surface water or the ground water system.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Ensure suitable personal protection during removal of spillages. Avoid dispersal of dust in the air. See Section 8.

Environmental precautions : Prevent entry into drains, sewers or watercourses. Collect spillage.

Methods and materials for containment and cleaning up : Transfer spilled capsules to a suitable container for disposal. Wash the spillage area with water. Avoid release to the environment. See section 13.

SECTION 7. HANDLING AND STORAGE

Advice on safe handling : In case of accident, avoid contact with skin and eyes. Wash hands after use. Minimize dust generation and accumulation. The product may form flammable dust clouds in air, if dust from capsules is allowed to accumulate .

Conditions for safe storage : Keep container tightly closed.

Recommended storage temperature : 20 - 25 °C

Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
 Date of first issue: 02.01.2018

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Olaparib	763113-22-0	TWA	0.0005 mg/m ³	COM

Engineering measures : The specific controls will depend on local circumstances and should be based on the risk assessment. Appropriate controls to reduce exposure may include engineering controls, for example ventilation, procedural controls and the use of personal protection equipment.

Prevent entry into drains, sewers or watercourses.
 See Section 6 for environmental precautions.

Personal protective equipment

- Respiratory protection** : Use an air fed hood if the risk assessment does not support the selection of other protection.
- Eye protection** : Use safety glasses to protect against direct contact with the product if the risk assessment does not support the selection of other protection.
- Skin and body protection** : Use full chemical protective suit to protect against direct contact with the product if the risk assessment does not support the selection of other protection. If the product is dissolved or wetted use a glove material that is resistant to the solvent/liquid. Take note of the information given by the PPE producer/supplier concerning permeability and breakthrough times and special workplace conditions.
- Protective measures** : Decisions about whether the use of personal protective equipment (PPE) is appropriate as part of the control strategy should be based on the workplace risk assessment and should take account of local legislative requirements for selection and use. There are multiple factors that will affect the specific requirements such as amount and concentration of the material, duration of exposure, frequency of exposure, external environmental conditions, the task, the user etc. All the information above should not be used in isolation and should be considered in the context of the workplace risk assessment on a case by case basis.

The recommended personal protective equipment (PPE) is based on preventing the potential adverse health effects from exposure to the active pharmaceutical ingredient (API). The risk of exposure to the API in the formulation/product needs to be taken into consideration.

SAFETY DATA SHEET



Version Revision Date: SDS Number: Date of last issue: -
2.0 02.01.2018 10313 Date of first issue: 02.01.2018

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : capsules

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/range : No data available

Initial boiling point and boiling : No data available
range

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : No data available

Upper explosion limit / Upper : No data available
flammability limit

Lower explosion limit / Lower : No data available
flammability limit

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Solubility(ies)

 Water solubility : No data available

 Solubility in other solvents : No data available

Partition coefficient: n- : No data available
octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

 Viscosity, dynamic : No data available

 Viscosity, kinematic : No data available

Explosive properties : No data available

SAFETY DATA SHEET



Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
Date of first issue: 02.01.2018

Oxidizing properties : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No known reactivity hazard under normal conditions.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : None known
Conditions to avoid : No conditions producing hazardous situations known.
Incompatible materials : None known.
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

11.1 Acute toxicity

Not classified based on available information.

Components:

Olaparib:

Acute oral toxicity : Oral minimum lethal dose (rat) is approximately: 240 - 300 mg/kg
Assessment: The component/mixture is toxic after single ingestion.
Acute inhalation toxicity : Remarks: May cause effects as described under repeated exposure.(STOT)
Acute dermal toxicity : Remarks: No information available.

11.2 Skin corrosion/irritation

Not classified based on available information.

Components:

Olaparib:

Remarks: Unlikely to be corrosive to the skin.

11.3 Serious eye damage/eye irritation

Not classified based on available information.

Components:

Olaparib:

Remarks: Unlikely to be a severe irritant to the eye.

Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
Date of first issue: 02.01.2018

11.4 Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Olaparib:

Remarks: It is not a skin sensitiser in vivo.
Unlikely to cause skin sensitisation.

Chronic toxicity

11.5 Germ cell mutagenicity

Not classified based on available information.

Components:

Olaparib:

Germ cell mutagenicity - Assessment : Evidence of secondary genotoxicity due to negative impact on DNA repair.

11.6 Carcinogenicity

Not classified based on available information.

Components:

Olaparib:

Carcinogenicity - Assessment : No evidence of carcinogenicity in animal studies.

11.7 Reproductive toxicity

May damage fertility or the unborn child.

Components:

Olaparib:

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Studies in animals have shown that low doses produce teratogenic effects and can reduce early embryofetal survival.

11.8 STOT - single exposure

Not classified based on available information.

Components:

Olaparib:

Exposure routes: Oral

Remarks: May cause effects as described under repeated exposure.(STOT)

Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
Date of first issue: 02.01.2018

11.9 STOT - repeated exposure

Causes damage to organs (Bone marrow, lymph node, spleen, Liver, Gastro-intestinal system) through prolonged or repeated exposure if swallowed.

Components:

Olaparib:

Exposure routes: Oral

Target Organs: Bone marrow, lymph node, spleen, Liver, Gastrointestinal tract

Assessment: Causes damage to organs through prolonged or repeated exposure.

Remarks: Studies in animals have shown that repeated doses cause effects on red and white blood cells and platelet count.

Remarks: Common side effects reported from patients include gastrointestinal disorders, headache, dizziness, fatigue and anaemia.

May cause reduced resistance to infection and increased risk of bleeding.

Based on haematology and pathology findings in a study in rats the No Adverse Effect Level was 25 mg/kg/day for females and 250 mg/kg/day for males.

11.10 Aspiration toxicity

Not classified based on available information.

Components:

Olaparib:

No information available.

Further information

Product:

Remarks: This health hazard assessment is based on a consideration of the composition of this product.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Product:

Ecotoxicology Assessment

Chronic aquatic toxicity : Harmful to aquatic life with long lasting effects.
Remarks: No information on this preparation.
The following information refers to active ingredient:
Olaparib

Components:

Olaparib:

Toxicity to daphnia and other aquatic invertebrates : NOEC (Daphnia magna (Water flea)): 74 mg/l
Exposure time: 48 H
Method: OECD Test Guideline 202

Toxicity to algae : NOEC (Pseudokirchneriella subcapitata (green algae)): 83 mg/l

SAFETY DATA SHEET



Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
Date of first issue: 02.01.2018

Exposure time: 72 H
Test Type: Growth inhibition
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.32 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.32 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : Respiration inhibition (Sewage sludge organisms): > 100 mg/l
Exposure time: 3 H
Test Type: EC50
Method: OECD Test Guideline 209

Ecotoxicology Assessment

Chronic aquatic toxicity : Toxic to aquatic life with long lasting effects.

Persistence and degradability

Components:

Olaparib:

Biodegradability : Result: Not rapidly biodegradable
Biodegradation: < 6 %
Exposure time: 28 d
Method: OECD Test Guideline 301F

Stability in water : Method: OECD Test Guideline 111
Remarks: The substance is not significantly hydrolyzed in water.

Bioaccumulative potential

Components:

Olaparib:

Bioaccumulation : Remarks: The substance has low potential for bioaccumulation.

Mobility in soil

Components:

Olaparib:

Mobility : Remarks: No information available.

Distribution among environmental compartments : Remarks: No information available.

SAFETY DATA SHEET



Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
Date of first issue: 02.01.2018

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

- Waste from residues : Disposal should be in accordance with local, state or national legislation.
Waste, even small quantities, should never be poured down drains, sewers or water courses.
Normal waste disposal is via incineration operated by an accredited disposal contractor.
- This material and its container must be disposed of as hazardous waste.
- Contaminated packaging : Empty container will retain residue. Observe all hazard precautions.
-

SECTION 14. TRANSPORT INFORMATION

Not classified as dangerous in the meaning of transport regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

In order to comply with legal duties it is necessary to consult local and national legislation.

Standard for the Uniform Scheduling of Medicines and Poisons : No poison schedule number allocated

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

REACH : Not listed

DSL : This product contains the following components that are not

SAFETY DATA SHEET



Version 2.0 Revision Date: 02.01.2018 SDS Number: 10313 Date of last issue: -
Date of first issue: 02.01.2018

on the Canadian DSL nor NDSL.

Olaparib 763113-22-0

AICS : Not listed

ENCS : Not listed

ISHL : Not listed

IECSC : Not listed

TCSI : Not listed

TSCA : Not On TSCA Inventory

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; CPR - Controlled Products Regulations; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Further information

Revision Date : 02.01.2018

Other information : The Safety Data Sheet has been updated to the SAP EH&S

SAFETY DATA SHEET

AstraZeneca 

 MedImmune

Version	Revision Date:	SDS Number:	Date of last issue: -
2.0	02.01.2018	10313	Date of first issue: 02.01.2018

Date format : Standard template., This update affects all Sections of the Safety Data Sheet., Minor changes:, 2, 4, 6, 15
: dd.mm.yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

AU / EN